Recent advances in the development of small molecule STK33 inhibitors.

Abstract

The serine/threonine kinase 33 (STK33) has attracted attention in recent years as a synthetic-lethal partner of oncogenic KRAS, thereby representing a potential indirect route to target KRAS-driven cancers. Initially, RNAi screens suggested that STK33 inhibition might selectively kill KRAS-mutant cells. Over the past decade medicinal chemistry, structural biology, and pharmacology efforts have yielded a variety of small-molecule probes and inhibitor series directed at STK33. In this review, we provide a comprehensive analysis of the state-of-the-art in STK33 small-molecule inhibitor development: we examine the biology and regulation of STK33, target validation strategies, discovery approaches (HTSfragment-based, structure-based), major chemical classes (benzimidazoles, thiazoles, pyrimidines/quinazolines, covalent and natural-product-inspired scaffolds), structure-activity relationship (SAR) trends, in vitro and in vivo pharmacology, translational challenges (selectivity, redundancy, resistance, pharmacokinetics) and future directions. We critically discuss the apparently conflicting evidence on STK33's essentiality in KRAS-driven cancers, and argue for refined targeting strategies of STK33 (including degradation rather than simply kinase inhibition) alongside biomarker-guided patient stratification. With continued optimization of pharmacokinetics, selectivity, and mechanism of action, STK33 remains a promising, albeit challenging, target in precision oncology.